Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients

Recent major clinical trials of the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes have shown that they reduce three‐point major adverse cardiovascular events, cardiovascular death, hospitalization for heart failure (HF) and a composite renal outcome. These...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Cutaneous Immunology and Allergy 2021-01, Vol.12 (1), p.6-20
Hauptverfasser:	Kashiwagi, Atsunori, Araki, Shinchi, Maegawa, Hiroshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adipose tissue Animals Antihypertensives Arteriosclerosis Blood pressure Calcium signalling Cardiomyocytes Cardiomyopathy Cardiovascular disease Cardiovascular diseases Clinical trials Congestive heart failure Creatinine Cytokines Dextrose Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes therapy Disease prevention Drug therapy Ejection fraction Energy metabolism Fibrosis Glucagon Glucose Heart attacks Heart failure Heart Failure - etiology Heart Failure - prevention & control Hemoglobin Humans Hyperglycemia Hyperlipidemia Hypoglycemic agents Inflammation Insulin Insulin resistance Kidney diseases Medical research Medicine, Experimental Metabolism Molecular modelling Na+/glucose cotransporter Nitric oxide Oxidative stress Peptides Prevention Review Risk factors Sodium Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Sodium–glucose cotransporter 2 inhibitor Type 2 diabetes Type 2 diabetes mellitus Uric acid Ventricle
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!